Additional immunosuppressants should be strongly considered and promptly given when immune-related adverse events (irAEs) associated with cancer immunotherapy aren’t quickly controlled with corticosteroids, Australian researchers say. Based on a case series of patients treated in Adelaide hospitals, they argue that there is no “compelling evidence” to indicate that immunosuppression will impair benefit from immunotherapy in ...
Early & aggressive immunosuppressive therapy needed for irAEs
By Sunalie Silva
5 Jul 2019